COMMUNIQUÉS West-GlobeNewswire

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
09/03/2026
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is [...]
Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
09/03/2026
PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik ® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les indications. La [...]
TimelyCare Launches TimelyPulse to Help Colleges Spot Struggling Students Before It’s Too Late
09/03/2026
New proactive engagement solution aims to close the gap between early signals and meaningful follow-through Fort Worth, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Colleges and universities have invested heavily in early [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
08/03/2026
Please see enclosed pdf. Attachment 08032026_trading_in_shares_GL
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
08/03/2026
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen [...]
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
08/03/2026
NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
08/03/2026
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary [...]
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
08/03/2026
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development [...]
MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions
07/03/2026
A 2026 informational consumer research report examining MagnesiumFreeze (Magnesium Niacinamide Relief) topical nerve support claims, ingredient research context, pricing disclosures, and verification considerations for [...]
AIM ImmunoTech Announces Closing of its Rights Offering
07/03/2026
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
06/03/2026
ZUG, Switzerland, March 06, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
NAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
06/03/2026
Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Dermalogic Laser Center Launches New, Upgraded Website
06/03/2026
The New Jersey Practice Has Unveiled Their New Site This Winter for an Enhanced User Experience HAMMONTON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Dermalogic Laser Center, a renowned aesthetic practice in Hammonton, [...]
Harvard Bioscience Announces Reverse Stock Split
06/03/2026
Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company [...]
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
06/03/2026
Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate pain In both ALLEVIATE trials [...]
Letter to Shareholders from CEO Dr. Ryan Saadi
06/03/2026
WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). Dear Shareholders, As we continue executing on Tevogen’s long-term strategy to evolve into a [...]
Crescent Biopharma Announces Grants of Inducement Awards
06/03/2026
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]

Pages